Form 4: Relay Therapeutics Insider Trades: CEO Sells Shares

Sanjiv Patel, President and CEO of Relay Therapeutics, has reported transactions involving the acquisition of shares through an Employee Stock Purchase Plan and the sale of shares under a Rule 10b5-1 trading plan.

Summary

• Sanjiv Patel, President and CEO of Relay Therapeutics, Inc., engaged in stock transactions on June 30, 2026, and July 7, 2026.
• On June 30, 2026, Patel acquired 3,056 shares of common stock through the company's 2020 Employee Stock Purchase Plan (ESPP) at a discounted price of $6.95 per share, representing 85% of the closing price on January 2, 2026.
• Following this acquisition, Patel beneficially owned 664,097 shares.
• On July 7, 2026, Patel sold 48,199 shares of common stock at a weighted average price of $19.58 per share, with prices ranging from $18.52 to $20.20.
• These sales were executed as part of a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025.
• After the sale, Patel's direct beneficial ownership was 615,898 shares.
• Additional shares are held indirectly through The Patel Family Irrevocable Trust of 2019 (199,548 shares) and The SSP Irrevocable Trust of 2020 (687,355 shares), for which Patel disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CEO sold shares, the transaction was conducted under a pre-established Rule 10b5-1 plan, which is a standard and compliant method for executives to manage their stock holdings.

Positives

• Acquisition of shares through the ESPP at a discount indicates participation in employee benefit programs.
• The sale of shares was conducted under a Rule 10b5-1 trading plan, suggesting pre-planned and potentially non-insider-trading-related transactions.

Negatives

• The CEO sold a significant number of shares (48,199), which could be perceived negatively by the market.
• The sale occurred at a price significantly higher than the ESPP purchase price, indicating a substantial gain for the selling executive.

Risks

• The sale of shares by a key executive could signal a lack of confidence in future stock performance, although the Rule 10b5-1 plan mitigates this interpretation.
• Potential for market perception of insider selling, despite the Rule 10b5-1 plan.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The reporting person disclaims beneficial ownership of securities held in irrevocable trusts for the benefit of family members, stating the filing is not an admission of beneficial ownership for Section 16 or any other purpose.
• The reporting person undertakes to provide full information regarding the number of shares sold at each respective price within the reported range upon request by the SEC, the Issuer, or a security holder.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by C-suite executives, are closely watched by investors. The use of a Rule 10b5-1 plan is a common strategy to allow executives to diversify their holdings or meet financial obligations without creating the appearance of trading on material non-public information. The specific details of the ESPP purchase at a discount and the subsequent sale at a higher price are typical for executive compensation and stock ownership plans within the biotechnology sector.

Related Party Transactions

• The acquisition of shares under the ESPP is a transaction between the reporting person and the issuer, facilitated by a company-sponsored plan.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO might be interpreted as a negative signal, although the Rule 10b5-1 plan mitigates concerns about insider trading. The ESPP purchase at a discount benefits the executive.
• Employees: The existence of the ESPP suggests a benefit available to employees, potentially encouraging stock ownership.
• Management: The transactions reflect the executive's personal financial planning and adherence to corporate governance policies regarding stock transactions.

Next Steps

• The reporting person may be required to provide further details on the sale prices upon request from regulatory bodies or security holders.
• Future filings will indicate any further changes in Sanjiv Patel's beneficial ownership.

Key Dates

Keywords

Form 4, Insider Trading, Stock Sale, Employee Stock Purchase Plan, Rule 10b5-1, Relay Therapeutics, RLAY, Sanjiv Patel, Beneficial Ownership, Executive Compensation